<DOC>
	<DOCNO>NCT00441337</DOCNO>
	<brief_summary>To evaluate safety , tolerability , efficacy , pharmacokinetics MDX-1106 administer patient advanced non-small cell lung cancer , colorectal cancer , malignant melanoma , clear cell renal cell cancer hormone refractory prostate cancer</brief_summary>
	<brief_title>A Study MDX-1106 Patients With Selected Refractory Relapsed Malignancies</brief_title>
	<detailed_description>Six patient enrol dose level 0.3 , 1.0 , 3.0 10mg/kg ; remain 10 15 patient may subsequently enrol dose maximum tolerate dose ( MTD ) dose-escalation portion study . Patients respond may receive additional dos drug .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed/refractory nonsmall cell lung cancer , colorectal adenocarcinoma , malignant melanoma , renal ( clear ) cell carcinoma , hormonerefractory prostate adenocarcinoma Prior treatment must complete least 4 week prior enrollment No untreated primary metastatic brain meningeal tumor ECOG PS 0 1 Meet screening laboratory value History severe hypersensitivity reaction monoclonal antibody Active autoimmune disease document history autoimmune disease Prior therapy antiPD1 antiCTLA4 antibody Active infection Concurrent medical condition require use immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>malignancy</keyword>
	<keyword>cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>malignant melanoma</keyword>
	<keyword>renal cancer</keyword>
	<keyword>renal carcinoma</keyword>
	<keyword>carcinoma</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostate adenocarcinoma</keyword>
	<keyword>Recurrent treatment refractory malignancy</keyword>
</DOC>